Quick Answer
Arbutus Biopharma Corp reported Research And Development Expense of $25.24 million for the year ending 2025.
- Arbutus Biopharma Corp showed a decrease of -53.3% in Research And Development Expense from 2024 to 2025.
- This data is from Arbutus Biopharma Corp's annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), Arbutus Biopharma Corp's Research And Development Expense has grown by 42.1%.
- Historical annual values: Fiscal year 2025: $25.24 million | Fiscal year 2024: $54.04 million | Fiscal year 2023: $73.70 million | Fiscal year 2022: $84.41 million | Fiscal year 2021: $65.50 million | Fiscal year 2020: $49.34 million | Fiscal year 2019: $57.60 million | Fiscal year 2018: $57.93 million | Fiscal year 2017: $62.68 million | Fiscal year 2016: $61.25 million | Fiscal year 2015: $51.51 million | Fiscal year 2014: $38.71 million | Fiscal year 2013: $21.46 million | Fiscal year 2012: $18.04 million | Fiscal year 2011: $20.13 million | Fiscal year 2010: $22.13 million | Fiscal year 2009: $17.76 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: